US Stock Market Move | Astera Labs (ALAB.US) continues to rise by over 10%, with a cumulative increase of 62% so far this year.
On Wednesday, Astera Labs (ALAB.US) continued to rise more than 10%, with a cumulative increase of 62% so far this year, now trading at $271.37.
On Wednesday, Astera Labs (ALAB.US) continued its increase by more than 10%, with a cumulative increase of 62% so far this year, and is now trading at $271.37. In terms of news, Astera Labs previously announced strong first-quarter performance and significantly raised its guidance for the next quarter. The financial report shows that Astera Labs' first-quarter revenue was $3.084 billion, an increase of 14% compared to the previous quarter and 93% year-on-year. CEO Jitendra Mohan stated that this was mainly driven by strong demand for their PCIe 6 product portfolio. Net profit was $80.3 million calculated according to US Generally Accepted Accounting Principles (GAAP); and $110.1 million calculated according to non-GAAP basis. Regardless of GAAP or non-GAAP measures, the gross profit margin remains at a high level of over 76%.
Astera Labs also impressed investors with their aggressive guidance for the second quarter. The company expects second-quarter revenue to be between $3.55 billion and $3.65 billion, with non-GAAP earnings per share (EPS) estimated at $0.68 to $0.70. Analysts pointed out that this performance outlook is at least 16% higher than Wall Street expectations, highlighting the company's important position as a core supplier of AI connectivity solutions for super-scale cloud service providers.
Related Articles

DEEPEXI TECH (01384) plans to discount approximately 19.78% of the placement of 7.942 million new H shares, raising approximately HK$395 million net.

JENSCARE-B(09877): The 12-month clinical follow-up results of patients with large valve disease who received the LuX-Valve Plus EU TRINITY research will be released at EuroPCR 2026, demonstrating the advantages of the product's large size.

New stock news | Zoomlion Heavy Industry submits an application to the Hong Kong Stock Exchange again as a mining equipment and aerial work equipment company.
DEEPEXI TECH (01384) plans to discount approximately 19.78% of the placement of 7.942 million new H shares, raising approximately HK$395 million net.

JENSCARE-B(09877): The 12-month clinical follow-up results of patients with large valve disease who received the LuX-Valve Plus EU TRINITY research will be released at EuroPCR 2026, demonstrating the advantages of the product's large size.

New stock news | Zoomlion Heavy Industry submits an application to the Hong Kong Stock Exchange again as a mining equipment and aerial work equipment company.






